Cargando…
Renal improvement and remission in a patient with refractory ANCA-associated vasculitis treated with avacopan
Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis is associated with end-organ damage resulting in significant morbidity and mortality. Most recently, avacopan, an orally administered selective antagonist of the C5a receptor, was approved by the US Food and Drug Administration as...
Autores principales: | Alvarez, Luis, Kambham, Neeraja, Su, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638159/ https://www.ncbi.nlm.nih.gov/pubmed/37036661 http://dx.doi.org/10.1007/s40620-023-01614-y |
Ejemplares similares
-
Journal Club Review of “Avacopan for the Treatment of ANCA‐Associated Vasculitis”
por: Soulsby, William Daniel
Publicado: (2022) -
Outcomes of COVID-19 in patients with ANCA-associated vasculitis receiving avacopan
por: Aqeel, Faten, et al.
Publicado: (2023) -
Avacopan improves patient perspective on steroid-related toxicity effects in a case with ANCA-associated vasculitis
por: Korsten, Peter, et al.
Publicado: (2023) -
Preliminary Assessment of Safety and Tolerability of Avacopan During the Early Access Program for ANCA-Associated Vasculitis
por: van Leeuwen, Jolijn R, et al.
Publicado: (2023) -
Compassionate Use of Avacopan in Difficult-to-Treat Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
por: van Leeuwen, Jolijn R., et al.
Publicado: (2021)